Q BioMed Inc. (QBIO)
Market Cap | 3.61M |
Revenue (ttm) | 270,656 |
Net Income (ttm) | -8.05M |
Shares Out | 31.43M |
EPS (ttm) | -0.31 |
PE Ratio | n/a |
Forward PE | 109.89 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 153,838 |
Open | 0.120 |
Previous Close | 0.110 |
Day's Range | 0.105 - 0.130 |
52-Week Range | 0.105 - 1.060 |
Beta | 1.71 |
Analysts | Buy |
Price Target | 6.12 (+5,221.7%) |
Earnings Date | n/a |
About QBIO
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership wi... [Read more...]
Analyst Forecast
According to 7 analysts, the average rating for QBIO stock is "Buy." The 12-month stock price forecast is 6.12, which is an increase of 5,221.74% from the latest price.
News

Q BioMed Outlines Strategy and Value Proposition in Multi-Billion Dollar Markets
Management's assessment and value of Q BioMed outlined NEW YORK , May 6, 2022 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) a commercial-stage biotechnology development company outlines its strategy and ...

Q BioMed announces publication of research showing augmented efficacy of its drug candidate Uttroside-B against liver...
NEW YORK , March 16, 2022 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) a commercial-stage biotechnology development company announces a new publication supporting the efficacy and further development of...

Q BioMed Announces Initial $500k Order of Strontium89 to Chinese Market
NEW YORK, March 7, 2022 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has received a confirmed $500,000 order for Strontium Chloride USP Inject...

Q BioMed Outlines Strategic Direction for 2022
NEW YORK, Feb. 14, 2022 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a biomedical acceleration and development company, focused on licensing, acquiring, and monetizing life science assets, outlines str...

Q BioMed Shows Significant Uptrend in Revenues in Year-End Update
NEW YORK, Dec. 16, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO ), a commercial-stage biotech company, provides this update to shareholders with positive trend in revenues, advancement in pipeline a...

Q BioMed Inc. Provides Shareholder Update
NEW YORK, Oct. 25, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthca...

Q BioMed Inc. Provides Update on Strontium89 Commercial Roll Out Revenue Up in 4th Quarter with Positive Trend
NEW YORK, Sept. 28, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcar...

Q BioMed Inc. Updates on COVID-19 Therapeutic Development and Clinical Trials - MAN-19 therapeutic program heading to...
NEW YORK, Sept. 22, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a commercial stage biotechnology acceleration company, is pleased to provide an update on its partner asset MAN-19 for the treatment ...

Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent in South Korea and Shows Promisin...
NEW YORK, Aug. 24, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare...

Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada
NEW YORK, Aug. 10, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has recently entered into an exclusive distribution agreement with isoSol...

Q BioMed Signs License Agreement with Clionix for the Distribution and Sales of Strontium89 in Europe and Middle East
NEW YORK, July 12, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has recently entered into an exclusive license agreement with Clionix, a ...

Q BioMed Inc. Discusses Progress of COVID-19 Therapeutic and $30 Million Potential Investment with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - June 23, 2021) - The Stock Day Podcast welcomed Q BioMed Inc. (OTCQB: QBIO) ("the Company"), a biotech acceleration and commercial stage company. CEO of the Company, ...

Q BioMed Engages Contract Sales Force with Deep VA and Oncology Experience
NEW YORK, May 20, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has hired WSI PBG, LLC (WSI), a Michigan based firm specializing in creat...

Q BioMed Insider to Invest up to $30M in the Company
NEW YORK, May 11, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO ), announced today that it has signed a securities purchase agreement ("Transaction") with Aedesius Holdings Ltd (AedesiusOne), a priva...

Q BioMed Updates Shareholders
NEW YORK, April 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, updates shareholders. In March 2021,it was announced that our technology partner, Mannin Researc...

Q BioMed Awarded Federal Supply Contract for Strontium89 with U.S. Department of Defense and Veterans Affairs
NEW YORK, March 2, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has signed an agreement for Strontium89 (Strontium Chloride Sr-89 Injecti...

Q BioMed Expands Strontium89 Reach Through Agreement with UroGPO, the Largest Group Purchasing Organization for Indep...
NEW YORK, Feb. 1, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has been awarded a contract with UroGPO, the largest Group Purchasing Orga...

Q BioMed's Uttroside-B Receives U.S. FDA Orphan Drug Designation in the Treatment of Liver Cancer
NEW YORK, Jan. 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), announced today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designatio...

Q BioMed Updates Shareholders at Year End
NEW YORK, Dec. 29, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, today issued a letter to shareholders. Dear Fellow Shareholders, As 2020 draws to a close, we joi...

Q BioMed Technology Partner Mannin Research Inc. Announced as Member of Canadian National COVID-19 Consortium
NEW YORK, Dec. 21, 2020 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) is pleased to announce that its technology partner Mannin Research Inc. (MRI), a private Canadian biotechnology company, is a member ...